









Markets
/
Stocks
/
nasdaq-lxrx
/

Lexicon Pharmaceuticals Inc

LXRX

1.515USD

-0.115-7.06%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

104.01MMarket Cap

LossP/E TTM



Lexicon Pharmaceuticals Inc

1.515

-0.115-7.06%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lexicon Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Lexicon Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 109 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.36.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lexicon Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

109 / 391

Overall Ranking

224 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Lexicon Pharmaceuticals Inc Highlights

StrengthsRisks

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 4036.46% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 49.80M.

Undervalued

The company’s latest PE is -11.90, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 263.45M shares, decreasing 12.83% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 594.88K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.62.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.360

Target Price

+106.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Lexicon Pharmaceuticals Inc is 5.66, ranking 339 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 5.49M, representing a year-over-year decrease of 79.31%, while its net profit experienced a year-over-year decrease of 54.01%.

Score

Industry at a Glance

Previous score

5.66

Change



Financials

5.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.88

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.69

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lexicon Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Lexicon Pharmaceuticals Inc is 5.98, ranking 340 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.90, which is -100.00% below the recent high of 0.00 and -4.24% above the recent low of -12.40.

Score

Industry at a Glance

Previous score

5.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Lexicon Pharmaceuticals Inc is 7.60, ranking 280 out of 391 in the Biotechnology & Medical Research industry. The average price target is 1.90, with a high of 6.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.360

Target Price

+103.64%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Lexicon Pharmaceuticals Inc

LXRX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Lexicon Pharmaceuticals Inc is 8.74, ranking 32 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.82 and the support level at 1.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.37

Change

1.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.037

Neutral

RSI(14)

45.003

Neutral

STOCH(KDJ)(9,3,3)

29.603

Sell

ATR(14)

0.108

Low Volatility

CCI(14)

-129.603

Sell

Williams %R

93.333

Oversold

TRIX(12,20)

0.426

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.638

Sell

MA10

1.619

Sell

MA20

1.643

Sell

MA50

1.506

Buy

MA100

1.406

Buy

MA200

1.285

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Lexicon Pharmaceuticals Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.68%, representing a quarter-over-quarter decrease of 4.25%. The largest institutional shareholder is The Vanguard, holding a total of 9.61M shares, representing 2.27% of shares outstanding, with 14.24% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Artal International S.C.A.

136.18M

Invus Public Equities Advisors, LLC

38.92M

Fidelity Management & Research Company LLC

38.68M

+1.42%

The Vanguard Group, Inc.

Star Investors

9.52M

+7.58%

Ulys, L.L.C.

5.45M

Millennium Management LLC

3.83M

+133.11%

BlackRock Institutional Trust Company, N.A.

3.17M

-0.12%

Sessa Capital

3.00M

Geode Capital Management, L.L.C.

2.40M

+0.85%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lexicon Pharmaceuticals Inc is 3.74, ranking 121 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.94. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.